secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2026-07-06T20:06:20+00:00
Accession:  0000879169-26-000048
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte completes $1.25B acquisition of Vega Therapeutics, adding Phase 3 VWD asset VGA039
--------------------------------------------------------------------------------

- Acquisition adds VGA039, a novel monoclonal antibody in Phase 3 for von Willebrand disease (VWD).
- Upfront payment of $1.25B; up to $750M in additional sales milestones for Star Therapeutics.
- VGA039 has Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease FDA designations.
- Transaction expected to be recorded as a one-time R&D expense in Q3 and full year 2026.
- VGA039 is in pivotal Phase 3 VIVID-6 study; potential first once-monthly subcutaneous prophylactic for VWD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000048/0000879169-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000048/incy-20260706.htm
  HTML page:      https://secwatch.observer/filing/0000879169-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer